PMID: 8612303Jan 1, 1996Paper

AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies

Cancer Chemotherapy and Pharmacology
S WebberB V Shetty

Abstract

3,4-Dihydro-2-amino-6 methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (AG337) is a water-soluble, lipophilic inhibitor of thymidylate synthase (TS) designed using X-ray structure - based methodologies to interact at the folate cofactor binding site of the enzyme. The aim of the design program was to identify TS inhibitors with different pharmacological characteristics from classical folate analogs and, most notably, to develop non-glutamate-containing molecules which would not require facilitated transport for uptake and would not undergo intracellular polyglutamylation. One molecule which resulted from this program, AG337, inhibits purified recombinant human TS with a Ki of 11 nM, and displays non-competitive inhibition kinetics. It was further shown to inhibit cell growth in a panel of cell lines of murine and human origin, displaying an IC50 of between 0.39 microM 6.6 microM. TS was suggested as the locus of action of AG337 by the ability of thymidine to antagonize cell growth inhibition and the direct demonstration of TS inhibition in whole cells using a tritium release assay. The demonstration, by flow cytometry, that AG337-treated L1210 cells were arrested in the S phase of the cell cycle was also consistent wi...Continue Reading

Citations

Sep 6, 2001·Archives of Pharmacal Research·S W OhD J Baek
Jul 13, 2005·Cancer Chemotherapy and Pharmacology·Olaf H TemminkGodefridus J Peters
Mar 3, 2007·Cancer Metastasis Reviews·Yehuda G Assaraf
Mar 23, 2005·Bioorganic & Medicinal Chemistry Letters·Sheng-Li CaoRun-Tao Li
Aug 9, 2002·Biochemical Pharmacology·Clasina L van der WiltGodefridus J Peters
Apr 16, 1998·Pharmacology & Therapeutics·W R Montfort, A Weichsel
May 24, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H H J BackusG J Peters
Aug 28, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Nitzan Gonen, Yehuda G Assaraf
May 15, 2010·Critical Reviews in Oncology/hematology·Jan P van MeerbeeckPaul Baas
Jul 16, 2010·Chemical Biology & Drug Design·Darren W BegleyGabriele Varani
Jun 16, 2004·International Journal of Pharmaceutics·M Merino-SanjuánN V Jiménez-Torres
Dec 1, 1999·Pharmaceutical Development and Technology·S RastogiR Suryanarayanan
Aug 24, 2000·International Journal of Cancer. Journal International Du Cancer·H H BackusG J Peters
Oct 25, 2003·Oncogene·Rongbao Zhao, I David Goldman
Oct 18, 2011·Expert Review of Anticancer Therapy·Veerle F Surmont, Jan P van Meerbeeck
Jun 24, 2009·Chemical Reviews·Mats Ljungman
Apr 26, 2005·Bioorganic & Medicinal Chemistry·Youhoon ChongDale L Boger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.